Glow LifeTech Corp.: Glow LifeTech Secures Canadian Processing Facility, Begins Build-out to Produce Next-Generation Cannabis Ingredients
Glow or the
Company ), a biotech innovator producing next-generation, science-backed natural ingredients, is pleased to report that the Company has commenced the build-out and commissioning of licensed processing space ( Processing Space ) to bring a suite of fast-acting, high-absorption, water-soluble cannabis-based ingredients to the Canadian market. The Processing Space is licensed for the processing and sale of cannabis under the Canadian Cannabis Act.
Glow s MyCell® technology is a proprietary plant-based delivery system developed in Switzerland which dramatically improves the absorption, bioavailability and effectiveness of natural active compounds including cannabinoids, vitamins, botanicals and more. The Company has secured the processing space by way of a long term engagement with a licensed facility that provides Glow the necessary
Article content
The results, announced on May 7, 2021, demonstrate the mechanism of action of ArtemiC™ is to reduce inflammation and suppress the cytokine storm
2 – believed to be the one of the leading causes of mortality in COVID-19 patients
3. The results show that ArtemiC™ decreases the markers of inflammation (IFN-g, IL-1a and TNF-a), in the bronchoalveolar lavage fluid (BALF) of mice in the animal model of cytokine storm related to COVID-19. The clinical and preclinical results to date support ArtemiC™ being effective for addressing cytokine overproduction which is found in different variants and mutations of COVID-19.
“ArtemiC™ focuses on preventing and reducing the severity of the cytokine storm and hyper-inflammation induced by respiratory viruses, and since all current COVID-19 variants of concern may lead to a cytokine storm, the preclinical and clinical results support that ArtemiC™ should be effective on COVID-19 variants,” said Tom Glawdel, PhD, Chi
Market Report: Lloyds jumps on UK economy optimism meanwhile Dixons close travel sector proactiveinvestors.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from proactiveinvestors.co.uk Daily Mail and Mail on Sunday newspapers.
TRADING UPDATES: Beximco s India jab mire; Lamprell gets Aramco deal
Wed, 28th Apr 2021 14:04
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:
Beximco Pharmaceuticals Ltd - Bangladesh-based generic pharmaceutical products and active pharmaceutical ingredients maker - Says agreement with Bangladeshi government and Serum Institute of India Pvt Ltd to deliver 30 million vaccine doses to Bangladesh is hit by India jabs export ban. Does not expect SII to be able to deliver remaining 23 million doses by end of June as India places ban on vaccine exports as cases there surge. The company will collaborate with SII to provide a revised supply schedule once the temporary export controls are relaxed. The expected positive impact on the current financial year, as outlined in the announcement on 5 November 2020, may therefore be mitigated, Beximco says. In addition, Beximco Pharma confirms